
Mefenamic Acid
We are a manufacturer based in China. We specialize in providing high-quality Mefenamic Acid for industrial clients across various sectors. Whether you need chemicals consultation or technical support, our team is here to help.
Category:Chemical Additives Own Brand:MT /MOQ:100KG /From China/ B2B only.
Introduction
Mefenamic Acid is an anti-inflammatory and analgesic drug with antipyretic, analgesic and anti-inflammatory effects. The analgesic effect is strong and the antipyretic effect is long-lasting, but the anti-inflammatory effect is not as good as that of Baotaisong and flufenamic acid.
1. Introduction
Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) belonging to the fenamate class. It is primarily used for its analgesic, anti-inflammatory, and antipyretic properties.
2. Mechanism of Action
– Inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
– Modulates pain and inflammation by blocking prostaglandin-mediated effects.
3. Therapeutic Uses
– Pain Relief: Effective for mild to moderate pain (e.g., headaches, dental pain, dysmenorrhea).
– Inflammatory Conditions: Used in rheumatoid arthritis and osteoarthritis (though less common than other NSAIDs).
– Menstrual Pain (Primary Dysmenorrhea):** One of its key indications due to strong prostaglandin inhibition.
4. Pharmacokinetics
– Absorption: Rapidly absorbed after oral administration (~50% bioavailability).
– Metabolism: Hepatic metabolism via CYP2C9.
– Excretion:Primarily renal (urine), with a half-life of **2–4 hours**.
5. Adverse Effects
– Common: GI disturbances (nausea, diarrhea, dyspepsia), dizziness, headache.
– Serious:
– GI ulcers/bleeding (higher risk than some NSAIDs).
– Renal impairment (especially in dehydrated or elderly patients).
– Hypersensitivity reactions (rash, Stevens-Johnson syndrome).
– Hepatotoxicity (rare but reported).
6. Drug Interactions
– Anticoagulants (e.g., warfarin): ↑ Bleeding risk.
– Diuretics/ACE inhibitors:Reduced efficacy due to fluid retention.
– Other NSAIDs/aspirin: ↑ GI toxicity.
7. Contraindications & Precautions
– Contraindicated in:
– Peptic ulcer disease.
– Severe renal/hepatic impairment.
– Asthma/NSAID-induced hypersensitivity.
– Use with caution in:
– Elderly patients.
– Cardiovascular disease (may ↑ BP).
8. Special Considerations
– Short-term use preferred (due to higher GI toxicity risk).
– Avoid in pregnancy (3rd trimester)—risk of premature ductus arteriosus closure.
9. Conclusion
Mefenamic acid is effective for acute pain and dysmenorrhea but carries significant GI and renal risks. Should be used at the **lowest effective dose for the shortest duration.
Basic Physicochemical Properties
| Property | Specification | Test Method |
|---|---|---|
| Chemical Name | 2-[(2.3-Dimethylphenyl)amino]benzoic acid | IUPAC nomenclature |
| Molecular Formula | C₁₅H₁₅NO₂ | Elemental analysis |
| Molecular Weight | 241.29 g/mol | Mass spectrometry |
| Appearance | White to pale yellow crystalline powder | Visual inspection |
| Solubility (25°C) | Practically insoluble in water, soluble in ethanol, acetone | USP <911> |
| Melting Point | 230–235°C | DSC analysis |
Pharmacological Profile
| Parameter | Value/Description | Reference Standard |
|---|---|---|
| Mechanism of Action | Non-selective COX inhibitor | FDA label |
| Bioavailability | ~90% (oral) | Clinical studies |
| Half-life (t₁/₂) | 2–4 hours | Pharmacokinetic data |
| Protein Binding | >90% | In vitro studies |
| Metabolism | Hepatic (CYP2C9-mediated) | EMA assessment report |
Therapeutic Applications & Dosage
| Medical Condition | Recommended Dosage | Maximum Daily Dose |
|---|---|---|
| Mild to moderate pain | 500 mg initial dose, then 250 mg every 6h | 1.500 mg |
| Primary dysmenorrhea | 500 mg loading dose, then 250 mg every 6h | 1.500 mg |
| Rheumatoid arthritis | 250–500 mg three times daily | 1.500 mg |
Pharmacopoeial Compliance
| Standard | Requirement | Compliance Status |
|---|---|---|
| USP-NF | Meets monograph standards | Compliant |
| Ph. Eur. | Conforms to EP 10.0 | Compliant |
| BP 2023 | Meets British Pharmacopoeia | Compliant |
| ICH Q3D (Impurities) | Heavy metals <20 ppm | Compliant |
| Residual Solvents | Class 2/3 limits per ICH Q3C | Compliant |
Stability & Storage Conditions
| Parameter | Specification |
|---|---|
| Storage temperature | 15–30°C (controlled room temp) |
| Shelf life | 36 months (unopened) |
| Light sensitivity | Protect from light |
| Packaging | HDPE bottles with desiccant |
| Regulatory status | FDA/EMA-approved prescription drug |
,Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
If you're ready to take the next step, Leave your message below and we’ll reply soon. 20+ years of chemical manufacturing & export experience, a partner you can trust.



